Last updated: May 29, 2026

Application No. 17/875,117

STABLE PEPTIDE FORMULATIONS FOR ORAL USE

Final Rejection

Filed

Jul 27, 2022

Priority

Jul 27, 2021 — IN 202141033678

Examiner

HELLMAN, KRISTINA M

Art Unit

1654

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Aurobindo Pharma Ltd

OA Round

4 (Final)

Interview Optional

— +54.3% interview lift. Examiner has a relatively high allowance rate (66%); +54.3% interview lift. A written response may suffice.

Based on 697 resolved cases, 2023–2026

Examiner Intelligence

HELLMAN, KRISTINA M View full profile →

Grants 66% — above average

Career Allowance Rate

460 granted / 697 resolved

+6.0% vs TC avg

Strong +54% interview lift

Without

With

+54.3%

Interview Lift

resolved cases with interview

Typical timeline

2y 5m

Avg Prosecution

49 currently pending

Career history

744

Total Applications

across all art units

Statute-Specific Performance

§101

2.8%

-37.2% vs TC avg

§103

37.3%

-2.7% vs TC avg

§102

6.9%

-33.1% vs TC avg

§112

17.4%

-22.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 697 resolved cases

Prosecution Timeline

Show 1 earlier event

Feb 27, 2024

Non-Final Rejection mailed

May 14, 2024

Response Filed

Aug 26, 2024

Final Rejection mailed

Nov 21, 2024

Request for Continued Examination

Feb 28, 2025

Response after Non-Final Action

Apr 28, 2025

Non-Final Rejection mailed

Jul 22, 2025

Response Filed

Sep 03, 2025

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/299,629

Patent 12624077

CXCR3 LIGAND

4y 11m to grant Granted May 12, 2026

18/524,472

Patent 12617830

ANALOGUES OF PYY

2y 5m to grant Granted May 05, 2026

17/761,664

Patent 12611446

Cannabinoid Product for Improving Musculoskeletal Health

4y 1m to grant Granted Apr 28, 2026

17/770,795

Patent 12599653

Thrombolytic Agents for Intravascular Clots

3y 11m to grant Granted Apr 14, 2026

17/630,645

Patent 12594319

PHARMACEUTICAL DEVELOPMENT

4y 2m to grant Granted Apr 07, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6

Expected OA Rounds

66%

Grant Probability

99%

With Interview (+54.3%)

2y 5m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 697 resolved cases by this examiner. Grant probability derived from career allowance rate.